The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Lu, Chunwan ^a,b   Redd, Priscilla S ^a,b   Lee, Jeffrey R ^a,b   Savage, Natasha ^a   Liu, Kebin ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

IFN ; MDSCs; MSI colon cancer; MSS colon cancer; PD L1; T cells

Indexed keywords

AZOXYMETHANE; BETA ACTIN; CELL SURFACE PROTEIN; DEXTRAN SULFATE; GAMMA INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNTING; CELL INFILTRATION; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN DNA INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

EID: 85007499773     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1247135     Document Type: Article

References (68)

1. + T Cells. PLoS One 2016; 11:e0155420; PMID:27171004; http://dx.doi.org/10.1371/journal.pone.0155420
2. Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, Labarriere N. PD-1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology 2016; 5:e1104448; PMID:26942093; http://dx.doi.org/10.1080/2162402X.2015.1104448
3. Lim TS, Chew V, Sieow JL, Goh S, Yeong JP, Soon AL, Ricciardi-Castagnoli P. PD-1 expression on dendritic cells suppresses CD8 T cell function and antitumor immunity. Oncoimmunology 2016; 5:e1085146; PMID:27141339; http://dx.doi.org/10.1080/2162402X.2015.1085146
4. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 2016; 29:1104-12; PMID:27198569; http://dx.doi.org/10.1038/modpathol
5. Dunne PD, McArt DG, O'Reilly PG, Coleman HG, Allen WL, Loughrey M, Van Schaeybroeck S, McDade S, Salto-Tellez M, Longley DB, et al. Immune-derived PD-L1 gene expression defines a subgroup of stage II/III colorectal cancer patients with favorable prognosis that may be harmed by adjuvant chemotherapy. Cancer Immunol Res 2016; 4:582-91; PMID:27197062; http://dx.doi.org/10.1158/2326-6066.CIR-15-0302
6. Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 2016; PMID:27196573; http://dx.doi.org/10.1136/gutjnl-2016-311421
7. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016; 22:813-20; PMID:26880610; http://dx.doi.org/10.1158/1078-0432.CCR-15-1678
8. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20; PMID:26028255; http://dx.doi.org/10.1056/NEJMoa1500596
9. Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer:the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology 2015; 4:e1058597; PMID:26140250; http://dx.doi.org/10.1080/2162402X.2015.1058597
10. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi.org/10.4161/onci.21335
11. Chawla A, Philips AV, Alatrash G, Mittendorf E. Immune checkpoints:A therapeutic target in triple negative breast cancer. Oncoimmunology 2014; 3:e28325; PMID:24843833; http://dx.doi.org/10.4161/onci.28325
12. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015; 5:43-51; PMID:25358689; http://dx.doi.org/10.1158/2159-8290.CD-14-0863
13. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
14. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
15. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c
16. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
17. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL, Hu J, Liu B, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One 2013; 8:e65821; PMID:23785454; http://dx.doi.org/10.1371/journal.pone.0065821
18. Hong S, Chen N, Fang W, Zhan J, Liu Q, Kang S, He X, Liu L, Zhou T, Huang J, et al. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC:Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology 2016; 5:e1094598; PMID:27141355; http://dx.doi.org/10.1080/2162402X.2015.1094598
19. Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 2015; 6:14209-19; PMID:25895031; http://dx.doi.org/10.18632/oncotarget.3694
20. Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Qin T, Tang Y, Zhang Y, Kang S, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma:Implications for oncotargeted therapy. Oncotarget 2014; 5:12189-202; PMID:25361008; http://dx.doi.org/10.18632/oncotarget.2608
21. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006; 580:755-62; PMID:16413538; http://dx.doi.org/10.1016/j.febslet.2005.12.093
22. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
23. Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual faces of IFN gamma in cancer progression:a role of pd-l1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res 2016; 22:2329-34; PMID:27016309; http://dx.doi.org/10.1158/1078-0432.CCR-16-0224
24. Blidner AG, Salatino M, Mascanfroni ID, Diament MJ, Bal de Kier Joffe E, Jasnis MA, Jasnis MA, Klein SM, Rabinovich GA. Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments. J Immunol 2015; 194:3452-62; PMID:25740944; http://dx.doi.org/10.4049/jimmunol.1401144
25. Cuenca AG, Cuenca AL, Winfield RD, Joiner DN, Gentile L, Delano MJ, Kelly-Scumpia KM, Scumpia PO, Matheny MK, Scarpace PJ, et al. Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia. J Immunol 2014; 192:6111-9; PMID:24829407; http://dx.doi.org/10.4049/jimmunol.1302895
26. Kim HK, Guan H, Zu G, Li H, Wu L, Feng X, Elmets C, Fu Y, Xu H. High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals. J Leukoc Biol 2006; 79:686-95; PMID:16461745; http://dx.doi.org/10.1189/jlb.0805436
27. Bai A, Szulc ZM, Bielawski J, Pierce JS, Rembiesa B, Terzieva S, Mao C, Xu R, Wu B, Clarke CJ, et al. Targeting (cellular) lysosomal acid ceramidase by B13:design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem 2014; 22:6933-44; PMID:25456083; http://dx.doi.org/10.1016/j.bmc.2014.10.025
28. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169:5538-45; PMID:12421930; http://dx.doi.org/10.4049/jimmunol.169.10.5538
29. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 2003; 100:5336-41; PMID:12697896; http://dx.doi.org/10.1073/pnas.0931259100
30. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 2011; 6:e27690; PMID:22110722; http://dx.doi.org/10.1371/journal.pone.0027690
31. Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest 2013; 123:4464-78; PMID:24091328; http://dx.doi.org/10.1172/JCI68189
32. Hu X, Bardhan K, Paschall AV, Yang D, Waller JL, Park MA, Nayak-Kapoor A, Samuel TA, Abrams SI, Liu K. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer. J Biol Chem 2013; 288:19103-15; PMID:23677993; http://dx.doi.org/10.1074/jbc.M112.434530
33. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment:expect the unexpected. J Clin Invest 2015; 125:3356-64; PMID:26168215; http://dx.doi.org/10.1172/JCI80005
34. Beury DW, Carter KA, Nelson C, Sinha P, Hanson E, Nyandjo M, Fitzgerald PJ, Majeed A, Wali N, Ostrand-Rosenberg S. Myeloid-derived suppressor cell survival and function are regulated by the transcription factor Nrf2. J Immunol 2016; 196:3470-8; PMID:26936880; http://dx.doi.org/10.4049/jimmunol.1501785
35. Guo C, Hu F, Yi H, Feng Z, Li C, Shi L, Li Y, Liu H, Yu X, Wang H, et al. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann Rheum Dis 2016; 75:278-85; PMID:25371442; http://dx.doi.org/10.1136/annrheumdis-2014-205508
36. Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol 2014; 96:1109-18; PMID:25170116; http://dx.doi.org/10.1189/jlb.3A0414-210R
37. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
38. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207:2439-53; PMID:20876310; http://dx.doi.org/10.1084/jem.20100587
39. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, Zhao K. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 2013; 8:e57114; PMID:23437326; http://dx.doi.org/10.1371/journal.pone.0057114
40. Liu Y, Zeng B, Zhang Z, Zhang Y, Yang R. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin Immunol 2008; 129:471-81; PMID:18790673; http://dx.doi.org/10.1016/j.clim.2008.07.030
41. Basso D, Fogar P, Falconi M, Fadi E, Sperti C, Frasson C, Greco E, Tamburrino D, Teolato S, Moz S, et al. Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen:role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study. PLoS One 2013; 8:e54824; PMID:23359812; http://dx.doi.org/10.1371/journal.pone.0054824
42. Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J, Jr., Taylor C, Zhang X. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 2015; 23:541-9; PMID:26317305; http://dx.doi.org/10.1097/PAI.0000000000000256
43. Wu X, Zhang H, Xing Q, Cui J, Li J, Li Y, Tan Y, Wang S. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer 2014; 111:1391-9; PMID:25093496; http://dx.doi.org/10.1038/bjc.2014.416
44. Zhao LW, Li C, Zhang RL, Xue HG, Zhang FX, Zhang F, Gai XD. B7-H1 and B7-H4 expression in colorectal carcinoma:correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem 2014; 116:1163-8; PMID:25053455; http://dx.doi.org/10.1016/j.acthis.2014.06.003
45. Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y, Zhou H, Li R, Wang K, Wang W, et al. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol 2014; 75:348-53; PMID:24468585; http://dx.doi.org/10.1016/j.humimm.2014.01.006
46. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
47. Papanikolaou A, Wang QS, Delker DA, Rosenberg DW. Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett 1998; 130:29-34; PMID:9751253; http://dx.doi.org/10.1016/S0304-3835(98)00101-3
48. Liu F, Bardhan K, Yang D, Thangaraju M, Ganapathy V, Waller JL, Liles GB, Lee JR, Liu K. NF-kappaB Directly Regulates Fas Transcription to Modulate Fas-mediated Apoptosis and Tumor Suppression. J Biol Chem 2012; 287:25530-40; PMID:22669972; http://dx.doi.org/10.1074/jbc.M112.356279
49. Kurotaki D, Yamamoto M, Nishiyama A, Uno K, Ban T, Ichino M, Sasaki H, Matsunaga S, Yoshinari M, Ryo A, et al. IRF8 inhibits C/EBPalpha activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils. Nat Commun 2014; 5:4978; PMID:25236377; http://dx.doi.org/10.1038/ncomms5978
50. Kim SH, Burton J, Yu CR, Sun L, He C, Wang H, Morse HC, 3rd, Egwuagu CE. Dual function of the IRF8 transcription factor in autoimmune uveitis:loss of irf8 in t cells exacerbates uveitis, whereas irf8 deletion in the retina confers protection. J Immunol 2015; 195:1480-8; PMID:26163590; http://dx.doi.org/10.4049/jimmunol.1500653
51. Jorgensen JT. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert Rev Mol Diagn 2016; 16:131-3; PMID:26559787; http://dx.doi.org/10.1586/14737159.2016.1117389
52. Ostrand-Rosenberg S. Tolerance and immune suppression in the tumor microenvironment. Cell Immunol 2016; 299:23-9; PMID:26435343; http://dx.doi.org/10.1016/j.cellimm.2015.09.011
53. Inamoto S, Itatani Y, Yamamoto T, Minamiguchi S, Hirai H, Iwamoto M, Hasegawa S, Taketo MM, Sakai Y, Kawada K. Loss of SMAD4 promotes colorectal cancer progression by accumulation of myeloid-derived suppressor cells through the CCL15-CCR1 chemokine axis. Clin Cancer Res 2016; 22:492-501; PMID:26341919; http://dx.doi.org/10.1158/1078-0432.CCR-15-0726
54. Chun E, Lavoie S, Michaud M, Gallini CA, Kim J, Soucy G, Odze R, Glickman JN, Garrett WS. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep 2015; 12:244-57; PMID:26146082; http://dx.doi.org/10.1016/j.celrep.2015.06.024
55. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015; 75:2139-45; PMID:25977340; http://dx.doi.org/10.1158/0008-5472.CAN-15-0255
56. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015; 112:1501-9; PMID:25867264; http://dx.doi.org/10.1038/bjc.2015.101
57. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3:1355-63; PMID:24078774; http://dx.doi.org/10.1158/2159-8290.CD-13-0310
58. Limagne E, Euvrard R, Thibaudin M, Rebe C, Derangere V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predict the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res 2016; 76:5241-52; PMID:27496709; http://dx.doi.org/10.1158/0008-5472.CAN-15-3164
59. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014; 2:361-70; PMID:24764583; http://dx.doi.org/10.1158/2326-6066.CIR-13-0127
60. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID:11323675; http://dx.doi.org/10.1038/35074122
61. Bardhan K, Paschall AV, Yang D, Chen MR, Simon PS, Bhutia YD, Martin PM, Thangaraju M, Browning DD, Ganapathy V, et al. IFNgamma induces DNA methylation-silenced GPR109A expression via pSTAT1/p300 and H3K18 acetylation in colon cancer. Cancer Immunol Res 2015; 3:795-805; PMID:25735954; http://dx.doi.org/10.1158/2326-6066.CIR-14-0164
62. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211:781-90; PMID:24778419; http://dx.doi.org/10.1084/jem.20131916
63. Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, Minoda Y, Sanada T, Yoshioka T, Mimata H, et al. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 2006; 203:1391-7; PMID:16717119; http://dx.doi.org/10.1084/jem.20060436
64. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 1991; 51:3657-62; PMID:1712245
65. Wang Y, Zhang Y, Yang J, Ni X, Liu S, Li Z, Hodges SE, Fisher WE, Brunicardi FC, Gibbs RA, et al. Genomic sequencing of key genes in mouse pancreatic cancer cells. Curr Mol Med 2012; 12:331-41; PMID:22208613; http://dx.doi.org/10.2174/156652412799218868
66. Wang B, Shi Q, Abbruzzese JL, Xiong Q, Le X, Xie K. A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. Int J Pancreatol 2001; 29:37-46; PMID:11558631; http://dx.doi.org/10.1385/IJGC:29:1:37
67. Srivastava MK, Dubinett S, Sharma S. Targeting MDSCs enhance therapeutic vaccination responses against lung cancer. Oncoimmunology 2012; 1:1650-1; PMID:23264925; http://dx.doi.org/10.4161/onci.21970
68. Simon PS, Sharman SK, Lu C, Yang D, Paschall AV, Tulachan SS, Liu K. The NF-kappaB p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription. BMC Cancer 2015; 15:770; PMID:26497740; http://dx.doi.org/10.1186/s12885-015-1808-6